Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Rheumatol Int. 2012 Aug;32(8):2285-92. doi: 10.1007/s00296-011-1958-z. Epub 2011 May 19.
The purpose of this study was to evaluate and compare the effectiveness of muscle-strengthening exercises (MS) and a walking program (WA) in reducing pain in patients with fibromyalgia. Ninety women, 30-55 years of age, diagnosed with fibromyalgia according to the American College of Rheumatology 1990 criteria, were randomized into 3 groups: WA Group, MS Group, and control group. Pain (visual analog scale) was evaluated as the primary outcome. Physical functioning (Fibromyalgia Impact Questionnaire, FIQ), health-related quality of life (Short-Form 36 Health Survey, SF-36), and use of medication were evaluated as secondary outcomes. Assessments were performed at baseline, 8, 16, and 28 weeks. Intention-to-treat and efficacy analyses were conducted. Sixty-eight patients completed the treatment protocol. All 3 groups showed improvement after the 16-week treatment compared to baseline. At the 28-week follow-up, pain reduction was similar for the WA and MS groups (P = 0.39), but different from the control group (P = 0.01). At the end of the treatment, 80% of subjects in the control group took pain medication, but only 46.7% in the WA and 41.4% in the MS groups. Mean FIQ total scores were lower for the WA and MS groups (P = 0.96) compared with the control group (P < 0.01). Patients in the WA and MS groups reported higher scores (better health status) than controls in almost all SF-36 subscales. MS was as effective as WA in reducing pain regarding all study variables; however, symptoms management during the follow-up period was more efficient in the WA group.
本研究旨在评估和比较肌肉强化运动(MS)和步行计划(WA)在减轻纤维肌痛患者疼痛方面的有效性。90 名年龄在 30-55 岁之间的女性,根据美国风湿病学会 1990 年的标准被诊断为纤维肌痛,随机分为 3 组:WA 组、MS 组和对照组。疼痛(视觉模拟评分)被评估为主要结局。身体功能(纤维肌痛影响问卷,FIQ)、健康相关生活质量(36 项简短健康调查,SF-36)和药物使用情况被评估为次要结局。评估在基线、8、16 和 28 周进行。进行意向治疗和疗效分析。68 名患者完成了治疗方案。所有 3 组在 16 周治疗后与基线相比均有所改善。在 28 周随访时,WA 和 MS 组的疼痛减轻与对照组相似(P=0.39),但与对照组不同(P=0.01)。在治疗结束时,对照组 80%的患者服用止痛药,但 WA 组只有 46.7%,MS 组只有 41.4%。WA 和 MS 组的 FIQ 总分均低于对照组(P=0.96),但对照组(P<0.01)。WA 和 MS 组的患者在几乎所有 SF-36 子量表中的报告得分(更好的健康状况)均高于对照组。MS 在所有研究变量方面与 WA 一样有效减轻疼痛;然而,WA 组在随访期间的症状管理更有效。